Home

Thomas Malley

CIK 1403322 · last filed 2026-06-04

Thomas Malley is a corporate insider who has filed 73 SEC Form 4 insider transactions across 7 companies since 2008. The most recent filing, for KURA, was dated Jun 4, 2026. Across all open-market trades the lifetime net is −$1.9M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $10.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$10.28M

Companies

7

Total Filings

73

Lifetime Open-Market Net

-$1.87M

Filer Profile

Reported Address
C/O KINIKSA PHARMACEUTICALS, LTD.
CLARENDON HOUSE, 2 CHURCH STREET
HAMILTON, D0 HM11
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
KURA Director 149,557 $13.25 $1.98M $975.0K 14 2026-06-04
KNSA Director 87,312 $77.91 $6.80M -$5.86M 11 2026-06-02
BeOne Medicines Ltd. (BGNE) Delisted Director 46,696 $184.71 $8.63M $960.0K 8 2023-06-20
Tempest Therapeutics, Inc. (OVAS) Delisted Director 13,665 — — $1.89M 16 2017-07-05
SYNAGEVA BIOPHARMA CORP (GEVA) Delisted Director 0 — — $0 6 2015-06-23
PBYI Director 156,551 $9.55 $1.50M $160.0K 4 2014-12-16
Cougar Biotechnology, Inc. (CGRB) Delisted Director 0 — — $0 2 2009-07-07

Recent Filings

73 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-04 KURA Grant (A) — $0 EDGAR
2026-06-02 KNSA Mixed +2,799 $0 EDGAR
2026-03-20 KURA Exer (M) +10,000 $31.2K EDGAR
2025-08-14 KNSA Notice (144) −78,233 -$2.59M EDGAR
2025-08-14 KNSA Mixed — -$4.04M EDGAR
2025-08-13 KNSA Notice (144) −50,129 -$1.67M EDGAR
2025-08-12 KNSA Notice (144) −49,407 -$1.60M EDGAR
2025-06-06 KURA Grant (A) — $0 EDGAR
2025-06-05 KNSA Mixed +3,173 $0 EDGAR
2024-06-07 KNSA Mixed +4,373 $0 EDGAR
Showing 1–10 of 73
Page 1 of 8
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.